[go: up one dir, main page]

PL1732574T3 - Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą - Google Patents

Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą

Info

Publication number
PL1732574T3
PL1732574T3 PL05707370T PL05707370T PL1732574T3 PL 1732574 T3 PL1732574 T3 PL 1732574T3 PL 05707370 T PL05707370 T PL 05707370T PL 05707370 T PL05707370 T PL 05707370T PL 1732574 T3 PL1732574 T3 PL 1732574T3
Authority
PL
Poland
Prior art keywords
atp
treatment
diseases involving
involving angiogenesis
angiogenesis
Prior art date
Application number
PL05707370T
Other languages
English (en)
Inventor
Maria Elena Ferrero
Original Assignee
Medestea Int S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Int S P A filed Critical Medestea Int S P A
Publication of PL1732574T3 publication Critical patent/PL1732574T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toilet Supplies (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05707370T 2004-02-17 2005-02-14 Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą PL1732574T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000255A ITMI20040255A1 (it) 2004-02-17 2004-02-17 Sostanze ad attivita' antiangiogenica
PCT/EP2005/001458 WO2005077383A1 (en) 2004-02-17 2005-02-14 The use of o-atp for the treatment of diseases involving angiogenesis
EP05707370A EP1732574B1 (en) 2004-02-17 2005-02-14 Use of o-atp for the treatment of diseases involving angiogenesis

Publications (1)

Publication Number Publication Date
PL1732574T3 true PL1732574T3 (pl) 2010-07-30

Family

ID=34856914

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05707370T PL1732574T3 (pl) 2004-02-17 2005-02-14 Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą

Country Status (16)

Country Link
US (1) US20070099864A1 (pl)
EP (1) EP1732574B1 (pl)
JP (1) JP2007522177A (pl)
KR (1) KR20070007786A (pl)
CN (1) CN1917887A (pl)
AT (1) ATE456371T1 (pl)
AU (1) AU2005211924A1 (pl)
BR (1) BRPI0507738A (pl)
CA (1) CA2556601A1 (pl)
DE (1) DE602005019142D1 (pl)
ES (1) ES2336011T3 (pl)
IT (1) ITMI20040255A1 (pl)
NO (1) NO20063686L (pl)
PL (1) PL1732574T3 (pl)
RU (1) RU2359679C2 (pl)
WO (1) WO2005077383A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2417758C1 (ru) * 2009-10-21 2011-05-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ оценки эффективности противоопухолевой терапии при нейробластомах у детей
FR3041260B1 (fr) * 2015-09-21 2020-10-02 Hopitaux Paris Assist Publique Utilisation d'un tripeptide cyclique pour stimuler l'activite mitochondriale de cellules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IT1318667B1 (it) * 2000-08-04 2003-08-27 Univ Degli Studi Milano Medicamento antinfiammatorio.
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses

Also Published As

Publication number Publication date
NO20063686L (no) 2006-08-16
EP1732574A1 (en) 2006-12-20
BRPI0507738A (pt) 2007-07-10
KR20070007786A (ko) 2007-01-16
CA2556601A1 (en) 2005-08-25
RU2006129748A (ru) 2008-02-27
JP2007522177A (ja) 2007-08-09
CN1917887A (zh) 2007-02-21
DE602005019142D1 (de) 2010-03-18
RU2359679C2 (ru) 2009-06-27
WO2005077383A1 (en) 2005-08-25
ATE456371T1 (de) 2010-02-15
ES2336011T3 (es) 2010-04-07
EP1732574B1 (en) 2010-01-27
AU2005211924A1 (en) 2005-08-25
US20070099864A1 (en) 2007-05-03
ITMI20040255A1 (it) 2004-05-17

Similar Documents

Publication Publication Date Title
UA85559C2 (en) Aminobenzophenone compounds
NL300933I2 (nl) Letermovir
MXPA05008478A (es) Heterociclos sustituidos.
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
GB0416508D0 (en) Therapeutic agents
WO2007047608A3 (en) Fibrin targeted therapeutics
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
ATE380188T1 (de) Substituierte chinolone
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PL1732574T3 (pl) Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą
WO2006089664A3 (de) Heterocyclylamid-substituierte imidazole
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
EP1865954A4 (en) METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER
PL371269A1 (pl) Pochodne benzimidazolu podstawione grupą 1-fenylo-2-heteroarylową, ich zastosowanie do wytwarzania środków leczniczych do leczenia schorzeń immunologicznych
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
TW200628453A (en) Triazole substituted aminobenzophenone compounds